<SEC-DOCUMENT>0001493152-21-023862.txt : 20210927
<SEC-HEADER>0001493152-21-023862.hdr.sgml : 20210927
<ACCEPTANCE-DATETIME>20210927163251
ACCESSION NUMBER:		0001493152-21-023862
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210916
FILED AS OF DATE:		20210927
DATE AS OF CHANGE:		20210927

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Thompson Bradley George
		CENTRAL INDEX KEY:			0001883869

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		211282089

	MAIL ADDRESS:	
		STREET 1:		1646 ACTON AVE. SW
		CITY:			CALGARY, ALBERTA
		STATE:			Z4
		ZIP:			T2T 2P9

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-09-16</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000890821</issuerCik>
        <issuerName>Enveric Biosciences, Inc.</issuerName>
        <issuerTradingSymbol>ENVB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001883869</rptOwnerCik>
            <rptOwnerName>Thompson Bradley George</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ENVERIC BIOSCIENCES,</rptOwnerStreet1>
            <rptOwnerStreet2>INC., 4851 TAMIAMI TRAIL N, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>NAPLES,</rptOwnerCity>
            <rptOwnerState>FL</rptOwnerState>
            <rptOwnerZipCode>34103</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Options</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.94</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2021-09-16</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>53160</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2021-09-16</value>
            </exerciseDate>
            <expirationDate>
                <value>2026-04-05</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>53160</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>53160</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the &quot;Amalgamation Agreement&quot;), by and among Enveric Biosciences, Inc. (the &quot;Company&quot;), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (&quot;HoldCo&quot;), 1306436 B.C. Ltd., (&quot;Purchaser&quot;), and MagicMed Industries Inc. (&quot;MagicMed&quot;), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the &quot;Exchange Ratio&quot;) multiplied by the number of MagicMed shares held by each such MagicMed shareholder.</footnote>
        <footnote id="F2">Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.</footnote>
        <footnote id="F3">Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.</footnote>
        <footnote id="F4">Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Thompson Bradley George</signatureName>
        <signatureDate>2021-09-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
